{"id":"NCT01387282","sponsor":"Helsinn Therapeutics (U.S.), Inc","briefTitle":"Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)","officialTitle":"Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-11","completion":"2015-02","firstPosted":"2011-07-04","resultsPosted":"2017-07-11","lastUpdate":"2017-10-27"},"enrollment":495,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cachexia","Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Anamorelin HCl","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"100 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.","primaryOutcome":{"measure":"Change in Lean Body Mass","timeFrame":"Change in Lean Body Mass from Baseline Over 12 Weeks","effectByArm":[{"arm":"Anamorelin HCl","deltaMin":0.65,"sd":null},{"arm":"Placebo","deltaMin":-0.98,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":15},"locations":{"siteCount":46,"countries":["United States","Australia","Hungary","Israel","Poland","Russia","United Kingdom"]},"refs":{"pmids":["39992021","28472437","26906526","25351456"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":73,"n":330},"commonTop":["Anaemia","Asthenia","Alopecia","Neutropenia","Nausea"]}}